CIRM issued a press release (PR) a few days ago unveiling CIRM 2.0, a new form of the agency and funding of novel efforts. The PR focused on action by its Governing Board to fund three Alpha Clinic programs for $8 million each at City of Hope (LA), UCLA, and UCSD. The Alpha Clinics will […]
CIRM 2.0 Launches Alpha Clinics & Continues Bridges Program Read More »
Stem cell-based Regenerative Medicine has huge power for good in the clinic and at the same time great potential for economic development. Those two things go hand in hand. As I argued in my stem cell book, biotech commercialization of stem cells is not a bad thing, but rather if it is done responsibly it
Reflecting on Regenerative Medicine As A Brand Read More »
I did a brief email Q&A interview with Dr. Bob Lanza of Advanced Cell Technology (ACT) on their new hES MSCs pre-clinical data for Multiple Sclerosis. I discussed the paper itself in a concise review yesterday here. Thanks to Dr. Lanza for doing the interview. 1. Were you surprised at the fact that the therapeutic
Interview with Bob Lanza on new ACT MSCs for MS paper Read More »
I just heard some very good news on the regenerative medicine front, a new Regenerative Medicine Bill. US Senators Barbara Boxer and Mark Kirk today introduced The Regenerative Medicine Promotion Act, which would keep track of and promote regenerative medicine efforts. This is really exciting and provides hope. One of the neat things about this
Great News: Senators Boxer & Kirk Introduce Regen Med Bill Read More »
What does the future hold for CIRM? I asked former CIRM Board Chair and Prop 71 leader, Robert Klein, about that and more in the interview below. He also says some particularly exciting clinical trial and other developments in the stem cell field are coming soon. What got you excited for the very first time
Interview with Robert Klein on CIRM’s Future Read More »
I recently posted on the dangerous situation with the Stamina Foundation. I discussed the controversy surrounding it that has impacted scientists, politicians, the media, and patients. Stamina’s unproven stem cell treatments in Italy should be of concern to everyone across the globe in the stem cell field. For example, here in the US where I
More on Stamina Foundation Controversy: Letter from Michele Simonato Read More »
Osiris, a cellular therapy biotech, recently received a so-called “untitled letter” from the FDA. The text of the letter seems on the whole negative in my opinion, while the company’s public reaction to the letter on the other hand could be seen paradoxically as rather cheery. What’s going on here? With Halloween coming, one has
Osiris FDA Letter: Trick or Treat? Read More »
This is a guest post on ISSCR 2013. By Dr. Susan Lim A record 4100 delegates attended the 11th Annual Meeting of the International Society for Stem Cell Research (ISSCR), held at the Convention and Exhibition Center in Boston from 12-15 June 2013. Co-sponsored by the Harvard Stem Cell Institute, the Meeting featured 7 Plenary
Delightful overview of ISSCR 2013 by guest blogger Dr. Susan Lim Read More »
One of the great areas of confusion over the human cloning development this week is whether human cloning is legal or illegal. With few exceptions, human cloning in general is legal in the US. Update: in 2020 it still appears that reproductive human cloning is legal in the US. It just hasn’t gotten that much
Deja you: human cloning generally legal in the US Read More »
Advanced Cell Technology (ACT) has confirmed that one of the patient in a clinical trial that it is running for treatment of macular degeneration, the leading cause of blindness worldwide, has shown a striking improvement in vision. The patient reportedly had 20/400 vision prior to treatment and now has 20/40 vision after treatment. ACT uses an
Striking improvement in vision in one ACT trial participant Read More »